Skip to content

Diego Pinzon Rubiano

2 papers in the library · 39 citations · publishing 2021-2023

Papers

Psychotherapeutic and neurobiological processes associated with ayahuasca: A proposed model and implications for therapeutic use

Frontiers in Neuroscience January 31, 2023 Daniel Perkins, Kimberley Day, Jerome Sarris et al. 27 citations

Ayahuasca, a psychoactive Amazonian brew containing DMT and harmala alkaloids, is increasingly used worldwide in traditional and neo-shamanic settings. A review of existing literature and original qualitative data from a large cross-sectional study of ayahuasca drinkers proposes a model of five key psychotherapeutic processes inherent to the experience: somatic effects, introspection and emotional processing, increased self-connection, increased spiritual connection, and gaining insights and new perspectives. These processes, facilitated by neurobiological effects, are argued to lead to beneficial mental health and wellbeing outcomes. The model highlights differences from other classic psychedelics and implications for therapeutic use.

Psychedelic medicines for mood disorders: current evidence and clinical considerations

Current Opinion in Psychiatry November 15, 2021 Jerome Sarris, Diego Pinzon Rubiano, Kimberley Day et al. 12 citations

Serotonergic psychedelics, including psilocybin, ayahuasca, LSD, and MDMA, show promise for treating mood disorders and PTSD, often combined with psychotherapy. Psilocybin with psychological support has been effective for depression, including treatment-resistant cases, in randomized placebo-controlled trials. LSD has shown anxiolytic effects, and MDMA has Phase III evidence for PTSD. Microdosing has not been found to improve mood in a controlled trial. Challenges remain with blinding, small sample sizes, and lack of definitive Phase III studies (except MDMA for PTSD). Further research into novel formulations, pharmacogenomics, microbiome interactions, and inflammatory pathways is needed.